WO2023062559 - INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
National phase entry:
Publication Number
WO/2023/062559
Publication Date
20.04.2023
International Application No.
PCT/IB2022/059780
International Filing Date
12.10.2022
Title **
[English]
INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
[French]
INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
Applicants **
VIIV HEALTHCARE UK (NO.5) LIMITED
GSK Medicines Research Centre
Gunnels Wood Road
Stevenage SG1 2NY, GB
Inventors
DALWADI, Gautam
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
Priority Data
63/255,056
13.10.2021
US
63/257,212
19.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3010 | |
| EPO | Filing, Examination | 31602 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 15910 |
Total: 51719 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
A pharmaceutical composition comprising the compound of Formula (Ia), or Formula (Ib), or a pharmaceutically acceptable salt thereof, is set forth.[French]
L'invention concerne une composition pharmaceutique comprenant le composé de formule Ia, de formule Ib ou un sel pharmaceutiquement acceptable correspondant, qui est présentée dans la description.